Serina Therapeutics, INC 8-K filings

Serina Therapeutics announced second quarter 2026 financial results, reporting progress in its SER-252 clinical trial and a strategic partnership, while also detailing operating expenses and net loss.

Serina Therapeutics, Inc. has amended and restated the employment agreement for its CEO, Steve Ledger, detailing salary, bonus structure, and severance packages.

Serina Therapeutics announced the appointment of Farrell Simon, Pharm. D., to its Board of Directors, effective July 22, 2026, who will also serve on the Audit and Compensation Committees.

Serina Therapeutics shareholders approved a significant increase in authorized common stock and amendments to the 2024 Equity Incentive Plan at the 2026 Annual Meeting.

Serina Therapeutics announced first-quarter 2026 financial results, highlighting progress in its Phase 1b registrational study for SER-252 in Parkinson's disease and the successful closing of a $21.2 million private placement.

Serina Therapeutics announced the appointment of a new CTO, an increase in CEO compensation, and amendments to its corporate bylaws.

Serina Therapeutics reported full-year 2025 financial results, highlighted by FDA clearance for SER-252, initiation of its Phase 1b trial, and a private placement financing of up to $30 million.

Serina Therapeutics announced a $15 million initial closing in a private placement, with potential for up to $30 million, to fund its SER-252 Parkinson's disease clinical trial.

Serina Therapeutics announced FDA clearance of its Investigational New Drug application for SER-252, an advanced Parkinson's disease therapy, paving the way for a Phase 1b clinical study.

Serina Therapeutics received a notification from NYSE American regarding non-compliance with minimum stockholders' equity requirements, potentially leading to delisting.

Serina Therapeutics submitted a complete response to the FDA's clinical hold letter for its lead Parkinson's disease program, SER-252, targeting first-patient-in for Q1 2026.

Serina Therapeutics announced its third quarter 2025 financial results, reporting a net loss and a clinical hold on its lead Parkinson's drug candidate, SER-252, while securing new financing.

Serina Therapeutics, Inc. stockholders approved the election of two directors, ratified auditors, and authorized a convertible note and warrants proposal at their 2025 Annual Meeting.

Serina Therapeutics announced the FDA has placed a clinical hold on its lead Parkinson's disease drug candidate, SER-252, requesting more information on a formulation component.

Serina Therapeutics announced the receipt of the first $5 million funding tranche from a previously announced $20 million agreement to advance its registrational trial for SER-252 in Parkinson's disease.

Serina Therapeutics, Inc. has secured up to $20 million in financing via a convertible note and warrants from board member Gregory H. Bailey, M.D., to fund its advanced Parkinson's Disease clinical study.

Serina Therapeutics announced a financing agreement for up to $20 million, led by Board Director Greg Bailey, MD, to advance its SER-252 registrational trial for Parkinson's disease.

Serina Therapeutics announced FDA feedback supports advancing SER-252 for advanced Parkinson's disease into a registrational clinical study program under the 505(b)(2) NDA pathway.

Serina Therapeutics, Inc. has amended its bylaws to establish safe harbor procedures for interested party transactions and expand its Delaware forum selection clause for stockholder claims.

Serina Therapeutics announced its second quarter 2025 financial results, highlighting progress in its clinical pipeline and securing additional funding.

Serina Therapeutics announced the advancement of its novel POZ-conjugated VMAT2 inhibitor, SER-270, for tardive dyskinesia, leveraging its proprietary POZ platform for once-weekly subcutaneous administration.

Serina Therapeutics, Inc. has announced November 7, 2025, as the date for its 2025 annual meeting of stockholders, establishing new deadlines for shareholder proposals and director nominations due to a change in the meeting schedule.

Serina Therapeutics appoints Dr. Stephen Brannan, a seasoned neuroscience drug developer, to its Board of Directors and announces the departure of Remy Gross.

Serina Therapeutics announced its Q1 2025 financial results, highlighting advancements in its SER-252 Parkinson's disease clinical trial and recent financing activities.

Serina Therapeutics has entered into a sales agreement with JonesTrading to offer and sell up to $13.27 million of its common stock through an at-the-market offering program.

Serina Therapeutics announces new data demonstrating its POZ-lipid technology as an immune-silent alternative to PEG-lipids in lipid nanoparticle (LNP) formulations, potentially addressing challenges related to anti-PEG antibodies.

Serina Therapeutics has secured $5 million in funding to support the clinical development of SER-252 for advanced Parkinson's disease.

Serina Therapeutics' CEO, Steve Ledger, will present at the Jones Healthcare and Technology Innovation Conference on April 9, 2025, showcasing the company's POZ Platform drug optimization technology.

Serina Therapeutics announced its full year 2024 financial results, highlighting a $10 million financing, the sale of its UniverXome subsidiary, and progress in its partnership with Enable Injections.

Serina Therapeutics' Chief Development Officer presented data at the ACS Spring 2025 Meeting demonstrating that their POZ-lipid technology does not trigger an antibody response, unlike PEG-lipids commonly used in LNP formulations.